Combination of Diosmetin With Chrysin Against Hepatocellular Carcinoma Through Inhibiting PI3K/AKT/mTOR/NF‐кB Signaling Pathway: TCGA Analysis, Molecular Docking, Molecular Dynamics, In Vitro Experiment

ABSTRACT Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy, and inflammation. Diosmetin and chrysin, are two flavonoid compounds, exhibit anti‐inflammatory and anticancer properties. In this study, the...

Full description

Saved in:
Bibliographic Details
Published inChemical biology & drug design Vol. 104; no. 4; pp. e70003 - n/a
Main Authors Yu, Xiang, Zhang, Di, Hu, Chengming, Yu, Zejun, Li, Yang, Fang, Cheng, Qiu, Yinsheng, Mei, Zhinan, Xu, Lingyun
Format Journal Article
LanguageEnglish
Published England 01.10.2024
Subjects
Online AccessGet full text
ISSN1747-0277
1747-0285
1747-0285
DOI10.1111/cbdd.70003

Cover

Loading…
Abstract ABSTRACT Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy, and inflammation. Diosmetin and chrysin, are two flavonoid compounds, exhibit anti‐inflammatory and anticancer properties. In this study, the TCGA database was utilized to identify differentially expressed genes between normal subjects and HCC patients. Molecular docking and molecular dynamics analyses were employed to assess the binding affinity of chrysin and diosmetin to key proteins in the PI3K/AKT/mTOR/NF‐κB signaling pathway. Western blotting and RT‐qPCR were used to measure the protein and gene expression within this pathway. The results indicated that HCC patients had elevated levels of PI3K, AKT, mTOR, and P65 proteins compared to normal subjects, which adversely affected patient survival. Molecular docking and dynamics studies demonstrated that diosmetin and chrysin are effectively bound to these four proteins. In vitro experiments revealed that the combination of diosmetin and chrysin could induce apoptosis, enhance autophagy, reduce inflammatory mediator production, and improve the tumor cell microenvironment by inhibiting the PI3K/AKT/mTOR/NF‐κB signaling pathway. Notably, the synergy score for the combination of diosmetin (25 μM) and chrysin (10 μM) was 16. Thus, the diosmetin–chrysin combination shows promise as an effective therapeutic approach for hepatocellular carcinoma due to its strong synergistic effect. In this study, we explored the mode of action of DIO and CHR with PI3K/AKT/mTOR/NF‐κB signaling pathway‐related proteins by molecular docking and molecular dynamics. We found that DIO combined with CHR could induce apoptosis and autophagy and inhibit the inflammatory factors in HepG2 cells by regulating the PI3K/AKT/mTOR/NF‐κB pathway.
AbstractList Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy, and inflammation. Diosmetin and chrysin, are two flavonoid compounds, exhibit anti‐inflammatory and anticancer properties. In this study, the TCGA database was utilized to identify differentially expressed genes between normal subjects and HCC patients. Molecular docking and molecular dynamics analyses were employed to assess the binding affinity of chrysin and diosmetin to key proteins in the PI3K/AKT/mTOR/NF‐κB signaling pathway. Western blotting and RT‐qPCR were used to measure the protein and gene expression within this pathway. The results indicated that HCC patients had elevated levels of PI3K, AKT, mTOR, and P65 proteins compared to normal subjects, which adversely affected patient survival. Molecular docking and dynamics studies demonstrated that diosmetin and chrysin are effectively bound to these four proteins. In vitro experiments revealed that the combination of diosmetin and chrysin could induce apoptosis, enhance autophagy, reduce inflammatory mediator production, and improve the tumor cell microenvironment by inhibiting the PI3K/AKT/mTOR/NF‐κB signaling pathway. Notably, the synergy score for the combination of diosmetin (25 μM) and chrysin (10 μM) was 16. Thus, the diosmetin–chrysin combination shows promise as an effective therapeutic approach for hepatocellular carcinoma due to its strong synergistic effect.
Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy, and inflammation. Diosmetin and chrysin, are two flavonoid compounds, exhibit anti-inflammatory and anticancer properties. In this study, the TCGA database was utilized to identify differentially expressed genes between normal subjects and HCC patients. Molecular docking and molecular dynamics analyses were employed to assess the binding affinity of chrysin and diosmetin to key proteins in the PI3K/AKT/mTOR/NF-κB signaling pathway. Western blotting and RT-qPCR were used to measure the protein and gene expression within this pathway. The results indicated that HCC patients had elevated levels of PI3K, AKT, mTOR, and P65 proteins compared to normal subjects, which adversely affected patient survival. Molecular docking and dynamics studies demonstrated that diosmetin and chrysin are effectively bound to these four proteins. In vitro experiments revealed that the combination of diosmetin and chrysin could induce apoptosis, enhance autophagy, reduce inflammatory mediator production, and improve the tumor cell microenvironment by inhibiting the PI3K/AKT/mTOR/NF-κB signaling pathway. Notably, the synergy score for the combination of diosmetin (25 μM) and chrysin (10 μM) was 16. Thus, the diosmetin-chrysin combination shows promise as an effective therapeutic approach for hepatocellular carcinoma due to its strong synergistic effect.Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy, and inflammation. Diosmetin and chrysin, are two flavonoid compounds, exhibit anti-inflammatory and anticancer properties. In this study, the TCGA database was utilized to identify differentially expressed genes between normal subjects and HCC patients. Molecular docking and molecular dynamics analyses were employed to assess the binding affinity of chrysin and diosmetin to key proteins in the PI3K/AKT/mTOR/NF-κB signaling pathway. Western blotting and RT-qPCR were used to measure the protein and gene expression within this pathway. The results indicated that HCC patients had elevated levels of PI3K, AKT, mTOR, and P65 proteins compared to normal subjects, which adversely affected patient survival. Molecular docking and dynamics studies demonstrated that diosmetin and chrysin are effectively bound to these four proteins. In vitro experiments revealed that the combination of diosmetin and chrysin could induce apoptosis, enhance autophagy, reduce inflammatory mediator production, and improve the tumor cell microenvironment by inhibiting the PI3K/AKT/mTOR/NF-κB signaling pathway. Notably, the synergy score for the combination of diosmetin (25 μM) and chrysin (10 μM) was 16. Thus, the diosmetin-chrysin combination shows promise as an effective therapeutic approach for hepatocellular carcinoma due to its strong synergistic effect.
ABSTRACT Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy, and inflammation. Diosmetin and chrysin, are two flavonoid compounds, exhibit anti‐inflammatory and anticancer properties. In this study, the TCGA database was utilized to identify differentially expressed genes between normal subjects and HCC patients. Molecular docking and molecular dynamics analyses were employed to assess the binding affinity of chrysin and diosmetin to key proteins in the PI3K/AKT/mTOR/NF‐κB signaling pathway. Western blotting and RT‐qPCR were used to measure the protein and gene expression within this pathway. The results indicated that HCC patients had elevated levels of PI3K, AKT, mTOR, and P65 proteins compared to normal subjects, which adversely affected patient survival. Molecular docking and dynamics studies demonstrated that diosmetin and chrysin are effectively bound to these four proteins. In vitro experiments revealed that the combination of diosmetin and chrysin could induce apoptosis, enhance autophagy, reduce inflammatory mediator production, and improve the tumor cell microenvironment by inhibiting the PI3K/AKT/mTOR/NF‐κB signaling pathway. Notably, the synergy score for the combination of diosmetin (25 μM) and chrysin (10 μM) was 16. Thus, the diosmetin–chrysin combination shows promise as an effective therapeutic approach for hepatocellular carcinoma due to its strong synergistic effect. In this study, we explored the mode of action of DIO and CHR with PI3K/AKT/mTOR/NF‐κB signaling pathway‐related proteins by molecular docking and molecular dynamics. We found that DIO combined with CHR could induce apoptosis and autophagy and inhibit the inflammatory factors in HepG2 cells by regulating the PI3K/AKT/mTOR/NF‐κB pathway.
Author Yu, Xiang
Xu, Lingyun
Fang, Cheng
Qiu, Yinsheng
Mei, Zhinan
Li, Yang
Yu, Zejun
Hu, Chengming
Zhang, Di
Author_xml – sequence: 1
  givenname: Xiang
  surname: Yu
  fullname: Yu, Xiang
  organization: Wuhan Polytechnic University
– sequence: 2
  givenname: Di
  surname: Zhang
  fullname: Zhang, Di
  organization: Wuhan Polytechnic University
– sequence: 3
  givenname: Chengming
  surname: Hu
  fullname: Hu, Chengming
  organization: Wuhan Polytechnic University
– sequence: 4
  givenname: Zejun
  surname: Yu
  fullname: Yu, Zejun
  organization: Wuhan Polytechnic University
– sequence: 5
  givenname: Yang
  surname: Li
  fullname: Li, Yang
  organization: Wuhan Polytechnic University
– sequence: 6
  givenname: Cheng
  surname: Fang
  fullname: Fang, Cheng
  organization: Wuhan Polytechnic University
– sequence: 7
  givenname: Yinsheng
  surname: Qiu
  fullname: Qiu, Yinsheng
  organization: Wuhan Polytechnic University
– sequence: 8
  givenname: Zhinan
  surname: Mei
  fullname: Mei, Zhinan
  organization: Huazhong Agricultural University
– sequence: 9
  givenname: Lingyun
  orcidid: 0000-0003-4350-5394
  surname: Xu
  fullname: Xu, Lingyun
  email: doctorxly9898@163.com
  organization: Wuhan Polytechnic University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39448547$$D View this record in MEDLINE/PubMed
BookMark eNp90UuOFCEYB3BixjgP3XgAw9IYe5oC6uWupnoenRkdoxVdVoCiutAqaIHKWDuP4BE8h0sPYDyDJ5HuHidxIxvgy48Pwv8Q7GmjJQCPI3QchTEXvGmOU4QQuQcOopSmM4SzeO9unab74NC5DwhRGuPsAdgnOaVZTNMD8LM0A1eaeWU0NC1cKOMG6ZWG75XvYNnZyYVNsWJKOw8v5Jp5I2Tfjz2zsGRWKG0GBqvOmnHVwaXuFFfh_Aq-XpLLeXFZzYfq-s381dnvL19_fT-Bb9VKs34LmO9u2PQCVuV5AYtQDXe55_Cl6aXY9l8Y8THIf0qTZoMSgS31j2_vlLcGnn5eS6sGqf1DcL9lvZOPbucjUJ2dVuXF7Or6fFkWVzOBs4zM4kTETYoE5iQTFEeESNYKTrCQeZ60DWIpi6K4SZomTliecJxQzjhFtMWyycgReLpru7bm0yidrwflNr_CtDSjq0mEUZwneZwH-uSWjnyQTb0OD2V2qv9GEMCzHRDWOGdle0ciVG_yrTf51tt8A452-Eb1cvqPrMuTxWJ35g89t6vM
Cites_doi 10.1007/s13167‐021‐00242‐5
10.1021/acs.jctc.8b01231
10.1038/s41572‐020‐00240‐3
10.1111/hepr.13259
10.1093/bioinformatics/bth449
10.3390/biom10101374
10.5152/tjg.2018.150318
10.1063/5.0004608
10.7717/peerj‐cs.584
10.1002/jcc.20291
10.3892/ol.2016.5347
10.1016/j.phymed.2021.153867
10.1002/jcc.22885
10.1016/j.tips.2014.11.004
10.1007/s11427‐023‐2499‐2
10.1016/j.phytochem.2017.09.016
10.1016/j.canlet.2015.07.018
10.1016/j.heliyon.2021.e06127
10.1016/j.taap.2021.115594
10.1016/j.drup.2024.101063
10.1038/s41419‐020‐02998‐6
10.1016/j.molliq.2022.119986
10.1002/1521‐3773(20020802)41:15<2644::Aid‐anie2644>3.0.Co;2‐o
10.3892/etm.2016.3282
10.1016/j.ijbiomac.2023.125836
10.3892/mmr.2016.4872
10.1016/j.canlet.2017.09.049
10.1111/j.1478‐3231.2006.01409.x
10.3390/biomedicines10030531
10.1016/j.jmb.2021.167290
10.1007/bf00197253
10.3390/biomedicines7030066
10.1038/s41580‐023‐00585‐z
10.1016/j.softx.2015.06.001
10.2147/cmar.S240064
10.1021/acs.jcim.0c00024
10.1021/acs.jcim.3c01153
10.1002/hep.32740
10.2174/0109298673259973231023110945
10.1053/jhep.2001.25387
10.1055/s‐0038‐1676806
10.3892/mmr.2016.5258
10.3892/or.2016.4973
ContentType Journal Article
Copyright 2024 John Wiley & Sons Ltd.
Copyright_xml – notice: 2024 John Wiley & Sons Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/cbdd.70003
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1747-0285
EndPage n/a
ExternalDocumentID 39448547
10_1111_cbdd_70003
CBDD70003
Genre researchArticle
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OC
29B
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGOF
ACMXC
ACPOU
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPT
EST
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
HF~
HGLYW
HVGLF
HZI
IHE
IX1
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N9A
NDZJH
O66
OIG
OVD
P2W
P4B
P4D
Q.N
Q11
QB0
Q~Q
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WIH
WIJ
WIK
WNSPC
WOHZO
WOW
WQJ
WRC
WXI
WXSBR
WYISQ
XG1
~IA
~KM
~WT
AAYXX
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ID FETCH-LOGICAL-c2883-56c5d70c2b38c42133eafcb32ce996fd0a7a115d6dd56a96b264bab404f2ed83
IEDL.DBID DR2
ISSN 1747-0277
1747-0285
IngestDate Fri Jul 11 04:28:31 EDT 2025
Wed Feb 19 02:12:43 EST 2025
Tue Jul 01 02:52:48 EDT 2025
Wed Jan 22 17:15:23 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords autophagy
PI3K/AKT/mTOR/NF‐кB signaling pathway
apoptosis
chrysin
molecular dynamics
hepatocellular carcinoma
diosmetin
Language English
License 2024 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2883-56c5d70c2b38c42133eafcb32ce996fd0a7a115d6dd56a96b264bab404f2ed83
Notes Xiang Yu and Di Zhang contributed equally to this work.
The authors received no specific funding for this work.
Funding
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4350-5394
PMID 39448547
PQID 3120596959
PQPubID 23479
PageCount 14
ParticipantIDs proquest_miscellaneous_3120596959
pubmed_primary_39448547
crossref_primary_10_1111_cbdd_70003
wiley_primary_10_1111_cbdd_70003_CBDD70003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2024
2024-10-00
2024-Oct
20241001
PublicationDateYYYYMMDD 2024-10-01
PublicationDate_xml – month: 10
  year: 2024
  text: October 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Chemical biology & drug design
PublicationTitleAlternate Chem Biol Drug Des
PublicationYear 2024
References 2019; 7
2018; 29
2021; 7
2015; 1–2
2015; 36
2004; 20
2023; 77
2022; 95
2020; 60
1985; 8
2018; 145
2021; 424
2019; 15
2019; 39
2024; 73
2023; 247
2020; 12
2020; 11
2020; 10
2005; 26
2012; 33
2017; 411
2018; 49
2016; 14
2022; 434
2016; 36
2016; 13
2016; 12
2022; 364
2023; 63
2023; 24
2021; 12
2002; 41
2023
2020; 152
2024; 67
2022; 10
2016; 379
2001; 34
2007; 27
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
e_1_2_7_38_1
e_1_2_7_39_1
References_xml – volume: 11
  start-page: 797
  year: 2020
  article-title: PI3K/AKT Pathway as a Key Link Modulates the Multidrug Resistance of Cancers
  publication-title: Cell Death & Disease
– volume: 12
  start-page: 5122
  year: 2016
  end-page: 5128
  article-title: Diosmetin Triggers Cell Apoptosis by Activation of the p53/Bcl‐2 Pathway and Inactivation of the Notch3/NF‐κB Pathway in HepG2 Cells
  publication-title: Oncology Letters
– volume: 63
  start-page: 6183
  year: 2023
  end-page: 6191
  article-title: AmberTools
  publication-title: Journal of Chemical Information and Modeling
– volume: 7
  year: 2021
  article-title: Hepatocellular Carcinoma
  publication-title: Nature Reviews Disease Primers
– volume: 1–2
  start-page: 19
  year: 2015
  end-page: 25
  article-title: GROMACS: High Performance Molecular Simulations Through Multi‐Level Parallelism From Laptops to Supercomputers
  publication-title: SoftwareX
– year: 2023
  article-title: Anti‐Migratory Properties of Cryoprotective Isoliquiritigenin‐Zein Phosphatidylcholine Nanoparticles Prevent Triple‐Negative Breast Cancer Through PI3K‐mTOR and MMP2/9 Pathways
  publication-title: Current Medicinal Chemistry
– volume: 10
  year: 2022
  article-title: Diosmetin Exerts Synergistic Effects in Combination With 5‐Fluorouracil in Colorectal Cancer Cells
  publication-title: Biomedicine
– volume: 39
  start-page: 26
  year: 2019
  end-page: 42
  article-title: Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
  publication-title: Seminars in Liver Disease
– volume: 424
  year: 2021
  article-title: Network Pharmacology and Molecular Docking Analysis on Molecular Targets: Mechanisms of Baicalin and Baicalein Against Hyperuricemic Nephropathy
  publication-title: Toxicology and Applied Pharmacology
– volume: 7
  year: 2021
  article-title: Machine Learning Analysis of TCGA Cancer Data
  publication-title: PeerJ Computer Science
– volume: 364
  year: 2022
  article-title: Electronic Structure Calculations of the Fundamental Interactions in Solvent Extraction Desalination
  publication-title: Journal of Molecular Liquids
– volume: 36
  start-page: 124
  year: 2015
  end-page: 135
  article-title: Current Treatment Strategies for Inhibiting mTOR in Cancer
  publication-title: Trends in Pharmacological Sciences
– volume: 24
  start-page: 560
  year: 2023
  end-page: 575
  article-title: Autophagy and Autophagy‐Related Pathways in Cancer
  publication-title: Nature Reviews Molecular Cell Biology
– volume: 95
  year: 2022
  article-title: Chrysin Inhibits Hepatocellular Carcinoma Progression Through Suppressing Programmed Death Ligand 1 Expression
  publication-title: Phytomedicine
– volume: 12
  start-page: 469
  year: 2016
  end-page: 474
  article-title: Chrysin Induces Cell Apoptosis via Activation of the p53/Bcl‐2/Caspase‐9 Pathway in Hepatocellular Carcinoma Cells
  publication-title: Experimental and Therapeutic Medicine
– volume: 152
  start-page: 224108
  year: 2020
  article-title: The ORCA Quantum Chemistry Program Package
  publication-title: Journal of Chemical Physics
– volume: 13
  start-page: 2401
  year: 2016
  end-page: 2408
  article-title: Diosmetin Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Downregulating the Expression Levels of MMP‐2 and MMP‐9
  publication-title: Molecular Medicine Reports
– volume: 73
  year: 2024
  article-title: Methylation of GPRC5A Promotes Liver Metastasis and Docetaxel Resistance Through Activating mTOR Signaling Pathway in Triple Negative Breast Cancer
  publication-title: Drug Resistance Updates
– volume: 12
  start-page: 155
  year: 2021
  end-page: 176
  article-title: Flavonoids as an Effective Sensitizer for Anti‐Cancer Therapy: Insights Into Multi‐Faceted Mechanisms and Applicability Towards Individualized Patient Profiles
  publication-title: EPMA Journal
– volume: 247
  year: 2023
  article-title: Molecular Dynamics Simulation and In Vitro Digestion to Examine the Impact of Theaflavin on the Digestibility and Structural Properties of Myosin
  publication-title: International Journal of Biological Macromolecules
– volume: 67
  start-page: 1849
  year: 2024
  end-page: 1866
  article-title: Ononin Inhibits Triple‐Negative Breast Cancer Lung Metastasis by Targeting the EGFR‐Mediated PI3K/Akt/mTOR Pathway
  publication-title: Science China Life Sciences
– volume: 36
  start-page: 1731
  year: 2016
  end-page: 1738
  article-title: Synergistic Inhibition of Characteristics of Liver Cancer Stem‐Like Cells With a Combination of Sorafenib and 8‐Bromo‐7‐Methoxychrysin in SMMC‐7721 Cell Line
  publication-title: Oncology Reports
– volume: 77
  start-page: 1773
  year: 2023
  end-page: 1796
  article-title: The Liver Cancer Immune Microenvironment: Therapeutic Implications for Hepatocellular Carcinoma
  publication-title: Hepatology
– volume: 60
  start-page: 5353
  year: 2020
  end-page: 5365
  article-title: Development and Evaluation of MM/GBSA Based on a Variable Dielectric GB Model for Predicting Protein‐Ligand Binding Affinities
  publication-title: Journal of Chemical Information and Modeling
– volume: 10
  year: 2020
  article-title: Broad‐Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
  publication-title: Biomolecules
– volume: 29
  start-page: 270
  year: 2018
  end-page: 282
  article-title: Autophagy and Liver Cancer
  publication-title: Turkish Journal of Gastroenterology
– volume: 411
  start-page: 82
  year: 2017
  end-page: 89
  article-title: Autophagy in the “Inflammation‐Carcinogenesis” Pathway of Liver and HCC Immunotherapy
  publication-title: Cancer Letters
– volume: 20
  start-page: 3705
  year: 2004
  end-page: 3706
  article-title: LimmaGUI: A Graphical User Interface for Linear Modeling of Microarray Data
  publication-title: Bioinformatics
– volume: 26
  start-page: 1701
  year: 2005
  end-page: 1718
  article-title: GROMACS: Fast, Flexible, and Free
  publication-title: Journal of Computational Chemistry
– volume: 41
  start-page: 2644
  year: 2002
  end-page: 2676
  article-title: Approaches to the Description and Prediction of the Binding Affinity of Small‐Molecule Ligands to Macromolecular Receptors
  publication-title: Angewandte Chemie International Edition
– volume: 49
  start-page: 14
  year: 2018
  end-page: 32
  article-title: Recent Advances in Medical Management of Hepatocellular Carcinoma
  publication-title: Hepatology Research
– volume: 15
  start-page: 3390
  year: 2019
  end-page: 3401
  article-title: Efficient Ensemble Refinement by Reweighting
  publication-title: Journal of Chemical Theory and Computation
– volume: 434
  year: 2022
  article-title: Pyroptosis in Kidney Disease
  publication-title: Journal of Molecular Cell Biology
– volume: 34
  start-page: 55
  year: 2001
  end-page: 61
  article-title: Expression and Role of Bcl‐xL in Human Hepatocellular Carcinomas
  publication-title: Hepatology
– volume: 7
  year: 2021
  article-title: Design, Docking, and DFT Investigations of 2, 6‐Bis (3, 4‐Dihydroxyphenyl)‐3‐Phenethylpiperidin‐4‐One
  publication-title: Heliyon
– volume: 7
  year: 2019
  article-title: Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
  publication-title: Biomedicine
– volume: 27
  start-page: 155
  year: 2007
  end-page: 162
  article-title: Survival and Apoptosis: A Dysregulated Balance in Liver Cancer
  publication-title: Liver International
– volume: 379
  start-page: 191
  year: 2016
  end-page: 197
  article-title: Heterogeneity of Liver Cancer and Personalized Therapy
  publication-title: Cancer Letters
– volume: 145
  start-page: 187
  year: 2018
  end-page: 196
  article-title: Chrysin: Sources, Beneficial Pharmacological Activities, and Molecular Mechanism of Action
  publication-title: Phytochemistry
– volume: 14
  start-page: 159
  year: 2016
  end-page: 164
  article-title: Diosmetin Induces Apoptosis by Upregulating p53 via the TGF‐β Signal Pathway in HepG2 Hepatoma Cells
  publication-title: Molecular Medicine Reports
– volume: 8
  start-page: 153
  year: 1985
  end-page: 164
  article-title: Immunomodulatory Peptides and the Central Nervous System
  publication-title: Springer Seminars in Immunopathology
– volume: 33
  start-page: 580
  year: 2012
  end-page: 592
  article-title: Multiwfn: A Multifunctional Wavefunction Analyzer
  publication-title: Journal of Computational Chemistry
– volume: 12
  start-page: 3537
  year: 2020
  end-page: 3546
  article-title: Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer
  publication-title: Cancer Management and Research
– ident: e_1_2_7_17_1
  doi: 10.1007/s13167‐021‐00242‐5
– ident: e_1_2_7_14_1
  doi: 10.1021/acs.jctc.8b01231
– ident: e_1_2_7_23_1
  doi: 10.1038/s41572‐020‐00240‐3
– ident: e_1_2_7_12_1
  doi: 10.1111/hepr.13259
– ident: e_1_2_7_38_1
  doi: 10.1093/bioinformatics/bth449
– ident: e_1_2_7_27_1
  doi: 10.3390/biom10101374
– ident: e_1_2_7_3_1
  doi: 10.5152/tjg.2018.150318
– ident: e_1_2_7_28_1
  doi: 10.1063/5.0004608
– ident: e_1_2_7_16_1
  doi: 10.7717/peerj‐cs.584
– ident: e_1_2_7_35_1
  doi: 10.1002/jcc.20291
– ident: e_1_2_7_30_1
  doi: 10.3892/ol.2016.5347
– ident: e_1_2_7_31_1
  doi: 10.1016/j.phymed.2021.153867
– ident: e_1_2_7_24_1
  doi: 10.1002/jcc.22885
– ident: e_1_2_7_5_1
  doi: 10.1016/j.tips.2014.11.004
– ident: e_1_2_7_9_1
  doi: 10.1007/s11427‐023‐2499‐2
– ident: e_1_2_7_26_1
  doi: 10.1016/j.phytochem.2017.09.016
– ident: e_1_2_7_15_1
  doi: 10.1016/j.canlet.2015.07.018
– ident: e_1_2_7_32_1
  doi: 10.1016/j.heliyon.2021.e06127
– ident: e_1_2_7_39_1
  doi: 10.1016/j.taap.2021.115594
– ident: e_1_2_7_29_1
  doi: 10.1016/j.drup.2024.101063
– ident: e_1_2_7_21_1
  doi: 10.1038/s41419‐020‐02998‐6
– ident: e_1_2_7_22_1
  doi: 10.1016/j.molliq.2022.119986
– ident: e_1_2_7_10_1
  doi: 10.1002/1521‐3773(20020802)41:15<2644::Aid‐anie2644>3.0.Co;2‐o
– ident: e_1_2_7_43_1
  doi: 10.3892/etm.2016.3282
– ident: e_1_2_7_19_1
  doi: 10.1016/j.ijbiomac.2023.125836
– ident: e_1_2_7_20_1
  doi: 10.3892/mmr.2016.4872
– ident: e_1_2_7_42_1
  doi: 10.1016/j.canlet.2017.09.049
– ident: e_1_2_7_8_1
  doi: 10.1111/j.1478‐3231.2006.01409.x
– ident: e_1_2_7_13_1
  doi: 10.3390/biomedicines10030531
– ident: e_1_2_7_37_1
  doi: 10.1016/j.jmb.2021.167290
– ident: e_1_2_7_11_1
  doi: 10.1007/bf00197253
– ident: e_1_2_7_33_1
  doi: 10.3390/biomedicines7030066
– ident: e_1_2_7_6_1
  doi: 10.1038/s41580‐023‐00585‐z
– ident: e_1_2_7_2_1
  doi: 10.1016/j.softx.2015.06.001
– ident: e_1_2_7_25_1
  doi: 10.2147/cmar.S240064
– ident: e_1_2_7_36_1
  doi: 10.1021/acs.jcim.0c00024
– ident: e_1_2_7_4_1
  doi: 10.1021/acs.jcim.3c01153
– ident: e_1_2_7_7_1
  doi: 10.1002/hep.32740
– ident: e_1_2_7_40_1
  doi: 10.2174/0109298673259973231023110945
– ident: e_1_2_7_34_1
  doi: 10.1053/jhep.2001.25387
– ident: e_1_2_7_41_1
  doi: 10.1055/s‐0038‐1676806
– ident: e_1_2_7_18_1
  doi: 10.3892/mmr.2016.5258
– ident: e_1_2_7_44_1
  doi: 10.3892/or.2016.4973
SSID ssj0044528
Score 2.403828
Snippet ABSTRACT Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy,...
Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor. Hepatocellular carcinogenesis is closely linked to apoptosis, autophagy, and...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage e70003
SubjectTerms Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
apoptosis
Apoptosis - drug effects
autophagy
Autophagy - drug effects
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - pathology
Cell Line, Tumor
chrysin
diosmetin
Flavonoids - chemistry
Flavonoids - pharmacology
Hep G2 Cells
hepatocellular carcinoma
Humans
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Liver Neoplasms - pathology
Molecular Docking Simulation
molecular dynamics
Molecular Dynamics Simulation
NF-kappa B - metabolism
Phosphatidylinositol 3-Kinases - metabolism
PI3K/AKT/mTOR/NF‐кB signaling pathway
Proto-Oncogene Proteins c-akt - metabolism
Signal Transduction - drug effects
TOR Serine-Threonine Kinases - antagonists & inhibitors
TOR Serine-Threonine Kinases - metabolism
Title Combination of Diosmetin With Chrysin Against Hepatocellular Carcinoma Through Inhibiting PI3K/AKT/mTOR/NF‐кB Signaling Pathway: TCGA Analysis, Molecular Docking, Molecular Dynamics, In Vitro Experiment
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcbdd.70003
https://www.ncbi.nlm.nih.gov/pubmed/39448547
https://www.proquest.com/docview/3120596959
Volume 104
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LjtNAEG2NZgMb_p_AgBrBCuEkdv8SxCbjTEhAM6DBwGyQ1d-JNYqNEkdoWHEEjsA5WHIAxBk4CV12HAhISLCzrPa3qrpfdVe_h9A9rQijhrAgCokLqHUukELIgHBBnLGKOg0ruvsHfPySPjliR1voUbMXpuaHWE-4QWRU_TUEuFSLX4JcK2PaoltTfUKxFiCiwzV3FKWsElb1iFtUC5UrblIo4_l56eZo9AfE3ESs1ZAzOo_eNC9bV5qctJelauv3v_E4_u_XXEDnVlgUD2rnuYi2bH4JnYkbCbjL6KvvLXzmXBkPFw4Ps2Ixgz3S-HVWTnE8nXsj53hwLDOPMvHYD21lAUsBUNuKY5ApyouZxEktBoQn-TRTGRRa4-cT8rTjAWZnljw77ByMvn_4-O3zLn6RHUNmAA08NH0nTx_iJH48wA13ygO83-j5Yj8-wjz_xqnTXM4y7ZtN8i-fXmXlvMB7aw2DKygZ7SXxOFgJQAQaRJADxjUzoqsjRXqaem8iVjrvXZG2Pk1zpiuF9IjWcGMYl32uPLpTUtEudZE1PXIVbedFbq8jbPvMhIoLxa2gXFvZBVZSzULd4zpkroXuNn6Qvq1pPtImPQLTpJVpWuhO4yKptwT8T5nbYrlISRiBjlGf9VvoWu076_vA1uMeo6KF7lce8JcHpPHucFgd3fiXxjfR2chjrbrGcAdtl_OlveWxUqluVzHxA5ncFAY
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LjtNAEG2hYTFs-H_C8GkEK4QTx91tJ-wyzoSEmQQ0mGF2Vn8n1ig2ShyhYcUROALnYMkBEGfgJHS140BAQoKdZbVt2VXletVd_R5Cj6QgjCrCvKBNjEe1MR6PIu6RMCJGaUGNhBXd8SQcvqbPj9nxqjcH9sJU_BDrCTeIDPe_hgCHCelfolwKpZqR77g-z4Okt6uoDtfsUZQyJ61qMXfklipX7KTQyPPz2s189AfI3MSsLukMLlXKqgvHVQi9JqfNZSma8v1vTI7__T6X0cUVHMW9yn-uoHM6v4q241oF7hr6an8Ytnh29sOFwf2sWMxgmzR-k5VTHE_n1s457p3wzAJNPLTZrSxgNQDaW3EMSkV5MeM4qfSA8CifZiKDXmv8ckT2WxZjtmbJi8PWZPD9w8dvn3fxq-wEigMYYNHpO372FCfxsx6u6VOe4HEt6YttioSp_o1TZzmfZdIOG-VfPh1l5bzAe2sZg-soGewl8dBbaUB4EnSQPRZKpiJfBoJ0JLUORTQ31sECqW2lZpTPI25BrQqVYiHvhsICPMEF9akJtOqQG2grL3J9C2HdZaotwkiEOqKh1NwHYlLJ2rITyjYzDfSwdoT0bcX0kdYVEpgmdaZpoAe1j6TWEvA9ea6L5SIl7QCkjLqs20A3K-dZ3wd2H3cYjRrosXOBvzwgjXf7fXd0-18G30fbw2R8kB6MJvs76EJgoVfVcngHbZXzpb5roVMp7rkA-QG35hgh
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtNAFB1VRQI25U3DcxCsEE5szytBbFK7IaE0VMWFbpA1z8ZCsavUESorPoFP4DtY8gGIb-BLmLHjQEBCgp1ljZ_33JlzZ-7cA8ADKRDBChEvDJDxsDbG44xxD1GGjNICG-lWdHfHdHiAnx2SwzXwpNkLU9eHWE64Oc-o-mvn4MfK_OLkUijVZn5V6vMMpn7XYTreXxaPwphUyqqWcrNqpXJRnNTl8fy8dnU4-oNjrlLWaswZXABvmretU03etuelaMv3vxVy_N_PuQg2FmQU9mv0XAJrOr8MzkWNBtwV8NV2FzZ0rqwHCwPjrDiZuk3S8HVWTmA0mVkr57B_xDNLM-HQjm1l4dYCXHIrjJxOUV5MOUxqNSA4yieZyFymNdwboZ2OZZidafJivzMefP_w8dvnLfgyO3KhgWtguek7fvoYJtHTPmyKpzyCu42gL7QDpJvoXzl1mvNpJm2zUf7l06usnBVweylicBUkg-0kGnoLBQhPOhVkj1BJFPNlKFBXYgsnpLmx8AqltnGaUT5n3FJaRZUilPeosPROcIF9bEKtuugaWM-LXG8CqHtEBYIyQTXDVGruu7KkkgSyS2VATAvcb3CQHtd1PtImPnKmSSvTtMC9BiKptYT7nzzXxfwkRUHohIx6pNcC12vsLO_j9h53CWYt8LBCwF8ekEZbcVwd3fiXxnfB2b14kD4fjXdugvOh5V11vuEtsF7O5vq25U2luFO5xw-I0BbZ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combination+of+Diosmetin+With+Chrysin+Against+Hepatocellular+Carcinoma+Through+Inhibiting+PI3K%2FAKT%2FmTOR%2FNF-%D0%BAB+Signaling+Pathway%3A+TCGA+Analysis%2C+Molecular+Docking%2C+Molecular+Dynamics%2C+In%C2%A0Vitro+Experiment&rft.jtitle=Chemical+biology+%26+drug+design&rft.au=Yu%2C+Xiang&rft.au=Zhang%2C+Di&rft.au=Hu%2C+Chengming&rft.au=Yu%2C+Zejun&rft.date=2024-10-01&rft.eissn=1747-0285&rft.volume=104&rft.issue=4&rft.spage=e70003&rft_id=info:doi/10.1111%2Fcbdd.70003&rft_id=info%3Apmid%2F39448547&rft.externalDocID=39448547
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1747-0277&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1747-0277&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1747-0277&client=summon